Revolution Medicines, Inc. Income Statement
RVMD / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Revolution Medicines, Inc. reported $0 in revenue and $1.1B in net loss for FY2025. Revenue has declined at a 10.5% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $43.0M | $50.0M | $20.2M | $50.0M | $20.2M |
| SG&A Expense | $195.0M | $97.3M | $75.6M | $21.4M | $12.4M | $9.4M | $12.4M | $9.4M |
| R&D Expense | $987.3M | $592.2M | $423.1M | $132.3M | $91.8M | $51.1M | $91.8M | $51.1M |
| Operating Income | -$1.2B | -$689.5M | -$487.2M | -$110.7M | -$54.1M | -$40.3M | -$54.1M | -$40.3M |
| Interest Expense | - | - | - | $71.0K | $106.0K | $116.0K | $106.0K | $116.0K |
| Income Tax | $0 | -$753.0K | -$3.5M | -$371.0K | -$4.4M | -$4.4M | -$4.4M | - |
| Net Income | -$1.1B | -$600.1M | -$436.4M | -$108.2M | -$47.7M | -$41.8M | -$47.7M | -$41.8M |
| EPS (Basic) | -$3.86 | -$3.08 | -$2.57 | -$2.01 | - | - | - | - |
| EPS (Diluted) | -$3.86 | -$3.08 | -$2.57 | -$2.01 | -$22.33 | -$21.24 | - | - |
| Shares Outstanding | 185.9M | 164.7M | 90.4M | 74.1M | 66.6M | 3.3M | 2.8M | 2.3M |
| Operating Margin | - | - | -4207.1% | -257.5% | -108.1% | -200.0% | - | - |
| Profit Margin | - | - | -3768.3% | -251.6% | -95.3% | -207.2% | -95.3% | - |